Factor VIII, Protein C and Cardiovascular Disease Risk: The REasons for Geographic and Racial Differences in Stroke Study (REGARDS)Funding Funding was received solely from the National Institutes of Health, Department of Health and Human Service, Bethesda, MD, USA. Grant numbers: U01 NS041588, K08 HL096841 and R01 HL080477. This research project is supported by a cooperative agreement U01 NS041588 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Service, Bethesda, MD, USA. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health. Representatives of the funding agency have been involved in the review of the manuscript but not directly involved in the collection, management, analysis or interpretation of the data. The authors thank the other investigators, the staff and the participants of the REGARDS study for their valuable contributions. A full list of participating REGARDS investigators and institutions can be found at http://www.regardsstudy.org.
Additional funding was provided by an investigator-initiated grant-in-aid K08HL096841 and R01HL080477 from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Service, Bethesda, MD, USA. Representatives from the National Heart, Lung, and Blood Institute did not have any role in the design and conduct of the study, the collection, management, analysis and interpretation of the data, or the preparation of the manuscript.
21. November 2017
15. April 2018
11. Juni 2018 (online)
Background Haemostatic balance represented by low protein C (PC) and elevated factor VIII (FVIII) has been inconsistently associated with stroke and coronary heart disease (CHD) risk.
Objective This article assesses whether an elevated FVIII and a low PC would increase cardiovascular risk more than either individually.
Patients and Methods REGARDS recruited 30,239 black and white U.S. participants aged ≥ 45 years between 2003 and 2007. FVIII and PC were measured in a case–cohort sample of 646 stroke, 654 CHD, and a 1,104-person random sample with follow-up for approximately 4.5 years. Hazard ratios (HRs) were estimated using Cox models adjusted for demographic and cardiovascular risk factors.
Results Elevated FVIII (per standard deviation [SD] increase) was associated with increased risk of both stroke (HR, 1.26; 95% confidence interval [CI], 1.08, 1.46) and CHD (HR, 1.52; 95% CI, 1.29, 1.79), while there was no association of PC per SD decrease. For PC, there was a trend towards increased cardiovascular disease risk in the lowest values (bottom 5%). For stroke, there was no interaction between FVIII and low PC (p interaction = 0.55). For CHD, the adjusted HR of FVIII per SD increase was significantly greater with PC in the bottom 5% (HR, 3.59; 95% CI, 1.39, 8.29) than PC in the upper 95% (HR, 1.45; 95% CI, 1.23, 1.71; p interaction = 0.07).
Conclusion Higher FVIII was associated with both CHD and stroke risk and the risk potentiated by low PC for CHD. Findings demonstrate that risks for cardiovascular diseases conferred by adverse levels of haemostasis biomarkers may be augmented by levels of other biomarkers.
Obtained funding: N.A. Zakai, M.M. Safford and G. Howard. Research design and methods: All authors. Statistical analyses: N.A. Zakai and S.E. Judd. Initial manuscript draft: N.A. Zakai. Critical revision and scientific review of the manuscript: All authors.
- 1 Dzau VJ, Antman EM, Black HR. , et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006; 114 (25) 2850-2870
- 2 Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 2005; 112 (20) 3080-3087
- 3 Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 2007; 115 (16) 2119-2127
- 4 Zakai NA, Katz R, Jenny NS. , et al. Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study. J Thromb Haemost 2007; 5 (06) 1128-1135
- 5 Smith NL, Bis JC, Biagiotti S. , et al. Variation in 24 hemostatic genes and associations with non-fatal myocardial infarction and ischemic stroke. J Thromb Haemost 2008; 6 (01) 45-53
- 6 Kucharska-Newton AM, Couper DJ, Pankow JS. , et al. Hemostasis, inflammation, and fatal and nonfatal coronary heart disease: long-term follow-up of the atherosclerosis risk in communities (ARIC) cohort. Arterioscler Thromb Vasc Biol 2009; 29 (12) 2182-2190
- 7 Bhatia M, Rothwell PM. A systematic comparison of the quality and volume of published data available on novel risk factors for stroke versus coronary heart disease. Cerebrovasc Dis 2005; 20 (03) 180-186
- 8 Soliman EZ, Safford MM, Muntner P. , et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med 2014; 174 (01) 107-114
- 9 Kumar G, Goyal MK. Warfarin versus aspirin for prevention of stroke in heart failure: a meta-analysis of randomized controlled clinical trials. J Stroke Cerebrovasc Dis 2013; 22 (08) 1279-1287
- 10 Force USPST. ; US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150 (06) 396-404
- 11 Soare AM, Popa C. Deficiencies of proteins C, S and antithrombin and activated protein C resistance--their involvement in the occurrence of Arterial thromboses. J Med Life 2010; 3 (04) 412-415
- 12 Folsom AR, Ohira T, Yamagishi K, Cushman M. Low protein C and incidence of ischemic stroke and coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. J Thromb Haemost 2009; 7 (11) 1774-1778
- 13 Folsom AR, Delaney JA, Lutsey PL. , et al; Multiethnic Study of Atherosclerosis Investigators. Associations of factor VIIIc, D-dimer, and plasmin-antiplasmin with incident cardiovascular disease and all-cause mortality. Am J Hematol 2009; 84 (06) 349-353
- 14 Rasche H. Haemostasis and thrombosis: an overview. Eur Heart J Suppl 2001; 3: 3-7
- 15 Esmon CT. The protein C pathway. Chest 2003; 124 (3, Suppl): 26S-32S
- 16 Howard VJ, Cushman M, Pulley L. , et al. The REasons for Geographic and Racial Differences in Stroke study: objectives and design. Neuroepidemiology 2005; 25 (03) 135-143
- 17 Howard VJ, Kleindorfer DO, Judd SE. , et al. Disparities in stroke incidence contributing to disparities in stroke mortality. Ann Neurol 2011; 69 (04) 619-627
- 18 Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 1999; 52 (12) 1165-1172
- 19 Kulathinal S, Karvanen J, Saarela O, Kuulasmaa K. Case-cohort design in practice - experiences from the MORGAM Project. Epidemiol Perspect Innov 2007; 4: 15
- 20 Zakai NA, Judd SE, Alexander K. , et al. ABO blood type and stroke risk: the REasons for Geographic and Racial Differences in Stroke Study. J Thromb Haemost 2014; 12 (04) 564-570
- 21 Gillett SR, Boyle RH, Zakai NA, McClure LA, Jenny NS, Cushman M. Validating laboratory results in a national observational cohort study without field centers: the Reasons for Geographic and Racial Differences in Stroke cohort. Clin Biochem 2014; 47 (16-17): 243-246
- 22 Howard G, Cushman M, Kissela BM. , et al; REasons for Geographic And Racial Differences in Stroke (REGARDS) Investigators. Traditional risk factors as the underlying cause of racial disparities in stroke: lessons from the half-full (empty?) glass. Stroke 2011; 42 (12) 3369-3375
- 23 Safford MM, Brown TM, Muntner PM. , et al; REGARDS Investigators. Association of race and sex with risk of incident acute coronary heart disease events. JAMA 2012; 308 (17) 1768-1774
- 24 Luepker RV, Apple FS, Christenson RH. , et al; AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation 2003; 108 (20) 2543-2549
- 25 Boekholdt SM, Kramer MH. Arterial thrombosis and the role of thrombophilia. Semin Thromb Hemost 2007; 33 (06) 588-596
- 26 Benjamin EJ, Blaha MJ, Chiuve SE. , et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: a report from the American Heart Association. Circulation 2017; 135 (10) e146-e603
- 27 Olson NC, Cushman M, Judd SE. , et al. Associations of coagulation factors IX and XI levels with incident coronary heart disease and ischemic stroke: the REGARDS study. J Thromb Haemost 2017; 15 (06) 1086-1094
- 28 Zakai NA, McClure LA, Judd SE. , et al. D-dimer and the risk of stroke and coronary heart disease. The REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Thromb Haemost 2017; 117 (03) 618-624
- 29 Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005; 111 (25) 3481-3488
- 30 Petty GW, Brown Jr RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 1999; 30 (12) 2513-2516
- 31 Peyvandi F, Palla R, Menegatti M. , et al; European Network of Rare Bleeding Disorders Group. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10 (04) 615-621
- 32 Srivastava A, Brewer AK, Mauser-Bunschoten EP. , et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (01) e1-e47
- 33 Tsai AW, Cushman M, Rosamond WD. , et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002; 113 (08) 636-642
- 34 Kamphuisen PW, ten Cate H. Cardiovascular risk in patients with hemophilia. Blood 2014; 123 (09) 1297-1301
- 35 Zakai NA, Olson NC, Judd SE. , et al. Haemostasis biomarkers and risk of intracerebral haemorrhage in the REasons for Geographic and Racial Differences in Stroke Study. Thromb Haemost 2017; 117 (09) 1808-1815
- 36 Ten Cate H, Hemker HC. Thrombin generation and atherothrombosis: what does the evidence indicate?. J Am Heart Assoc 2016; 5 (08) e003553
- 37 Zakai NA, Ohira T, White R, Folsom AR, Cushman M. Activated partial thromboplastin time and risk of future venous thromboembolism. Am J Med 2008; 121 (03) 231-238